Phage Display Antibody Mapping for Mutation Screening
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evolving target molecules, such as antibodies, face challenges in accurately measuring subtle changes in performance, especially when sensitive assays are not available, and struggle with the rapid increase in combinations of simultaneous mutations, which exceeds cloning and screening capabilities.
Innovation Solution
A method is developed to map a population of mutant antibodies by generating sets with different amino acid residues at specific positions, assaying for predetermined properties, and creating a functional positional map to identify improvements or neutral mutations, allowing for targeted optimization of protein stability, solubility, and binding affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If single point mutations are generated and screened to improve target protein characteristics, then improved mutants can be identified, but the method fails when sensitive assays do not exist to accurately measure subtle performance changes
Solution Approach 1:
The patent introduces an intermediary system (phage display with M13 bacteriophage) that mediates between the antibody mutant and the detection system. The antibody is fused to the phage coat protein, allowing the phage itself to serve as a visual indicator of binding activity through ELISA detection, thus creating a measurable signal for subtle performance changes without requiring highly sensitive direct assays.
Solution Approach 2:
The patent replaces the need for sensitive biochemical assays with a simpler immunological detection system. By using phage display and ELISA, the system substitutes complex sensitivity requirements with a robust antibody-antigen detection mechanism that can reliably measure binding characteristics of mutant antibodies.
2Adaptability or versatility
If simultaneous mutations of several sites are performed to optimize desired characteristics, then more comprehensive optimization is achieved, but the number of combinations increases very quickly exceeding cloning efficiency and screening capability
Solution Approach 1:
The patent segments the mutation process into two distinct phases: first generating a diverse library of single-point mutants through error-prone PCR, then performing directed evolution through iterative rounds of selection and recombination. This segmentation breaks down the overwhelming task of simultaneous multi-site mutagenesis into manageable steps that maintain cloning and screening feasibility while achieving comprehensive optimization over multiple generations.
Solution Approach 2:
The patent performs preliminary action by first establishing a robust single-mutant library and characterizing individual mutation effects before proceeding to combination strategies. This preliminary characterization provides a foundation for understanding which mutations are beneficial, allowing subsequent rounds to focus on combining known good mutations rather than randomly exploring all possible combinations.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is relevant to proteins and novel methods of protein evolution. The present invention further relates to methods of identifying and mapping mutant polypeptides formed from, or based upon, a template polypeptide.